Drug intelligence / Profile preview

AdimrSC-2f

Development stage: Phase 2
Lead developer: Adimmune
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AdimrSC-2f is a subunit protein-based vaccine developed to prevent Coronavirus disease 2019 (COVID-19). It is produced using the baculovirus insect cell expression system and contains the SARS-CoV-2 spike protein as its antigen. The vaccine aims to induce an immune response against SARS-CoV-2, specifically targeting the spike protein, which mediates viral entry into host cells. AdimrSC-2f was developed by Adimmune Corporation and has reached Phase 1/2 clinical trials for COVID-19 prevention[1][2][4][8].

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on AdimrSC-2f.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdimrSC-2f.

Explore the full profile